Showing 13 - 24 of 71 reports matching: Metabolic Disorders
Journals
Specialties
Date of Publication
to
Synopsis: 540 postmenopausal women with normal to low bone mineral density were randomized to 24 months of treatment with either lasofoxifene 0.25mg/day, raloxifene 60mg/day, or daily placebo. The purpose of this study was to compare changes in bone mineral density and bone turnover markers between groups after 24 months of treatment. Change in bone Read More »
Conference Report
Synopsis: A subset of 164 women from the Long-Term Odanacatib Fracture Trial were included in this imaging sub-study to evaluate the effect of odanacatib versus placebo on volumetric bone mineral density (vBMD) of the lumbar spine and total hip. Follow-up was made at 24 months of treatment, and percent change in trabecular vBMD of the lumbar spine and cortical vBMD of total hip were compared. Results demonstrated a Read More »
Conference Report
Synopsis: 643 postmenopausal women with osteoporosis who had been administered oral bisphosphonates for 2 or more years prior to enrollment were randomized to be administered either denosumab or zoledronic acid. The purpose of this study was to compare the change in bone mineral density (BMD) and bone turnover markers after 1 year. Results demonstrated a Read More »
Conference Report
Synopsis: 80 patients with osteoporosis were randomized to receive either alfacalcidol, a vitamin D analogue, or plain vitamin D (cholecalciferol). Both treatment groups also received calcium supplementation and alendronate. The purpose of Read More »
Conference Report
Synopsis: 8 randomized controlled trials (30,970 adults) comparing calcium with vitamin D supplementation against no supplementation or a placebo in an adult population were included in this study. The purpose of this meta-analysis was to analyze the effect of calcium and vitamin D supplementation on fracture prevention (total and hip) in adults. The results displayed Read More »
Level 2 Meta Analysis
Synopsis: 2463 postmenopausal women with osteoporosis were randomized to one of three groups: daily subcutaneous abaloparatide (80ug), daily subcutaneous teriparatide (20ug), or daily subcutaneous placebo. The treatment period was 18 months, and patients were assessed for bone mineral density and incident fracture rate. Abaloparatide treatment was Read More »
Conference Report
Synopsis: 6 randomized controlled trials, including a total of 833 patients, were analyzed to evaluate the efficacy of combined parathyroid hormone (PTH) and alendronate administration in the treatment of osteoporosis. The meta-analysis assessed mean percent increases in bone mineral density (BMD) at the lumbar spine, femoral neck, total hip, and distal radius with combination therapy compared to monotherapy of PTH or teriparatide alone. Results demonstrated no Read More »
Level 1 Meta Analysis
Synopsis: 79 elderly patients with femoral neck or trochanteric hip fractures were randomized to a group receiving protein-rich supplementation and weekly bisphosphonates, weekly bisphosphonates alone, or a control group; all three groups received calcium and vitamin D supplementation. The purpose of this randomized controlled trial was to compare these treatments in terms of their effect on body composition, hand-grip strength, and quality of life. The results displayed Read More »
Level 2 RCT
Synopsis: 219 postmenopausal Chinese women with osteoporosis were randomized to receive one of two medications: a weekly dose of alendronate sodium with vitamin D3 (ALN/D5600) or a daily dose of calcitriol. The purpose of the study was to determine if ALN/D5600 provided greater benefits for bone mineral density and other measures of osteoporosis compared to calcitriol and to assess the safety of alendronate treatment. ALN/D5600 resulted in Read More »
Level 2 RCT
Synopsis: 81 post-menopausal women diagnosed with osteopenia were randomly assigned to receive either 1mg, 3mg of melatonin placebo at night for 12 months in order to determine the effects of melatonin on bone mineral density. The results of Read More »
Level 2 RCT
Synopsis: Eighty postmenopausal women with osteoporosis were randomized to one of three treatment groups: one received 2.5 units of growth hormone per day for 3 years; one received 1 unit of growth hormone per day for 3 years; one received placebo every day for 18 months. The double-blind phase of the trial lasted up to 18 months. The purpose of Read More »
Author verified Level 2 RCT
Synopsis: 9 randomized controlled trials, including 2464 patients, were included is this meta-analysis and systematic review, for the purpose of analyzing the efficacy of bisphosphonate therapy compared to placebo in males with osteoporosis. Results showed that Read More »
Level 1 Meta Analysis